Anti-VEGFs represent ‘a sea change’ in diabetic macular oedema

Patients requiring anti-VEGF (vascular endothelial growth factor ) therapy for diabetic macular oedema (DME) can be reassured that their need for injections will most likely decrease over time. Associate Professor Jennifer Sun, from the Harvard Department of Ophthalmology and the Joslin Diabetes Centre, said a typical regimen might include 8-9 injections in year 1, two ...

Already a member?

Login to keep reading.

© 2021 the limbic